“To Randomize, or Not to Randomize, That is the Question”
Copyright policy )“To Randomize, or Not to Randomize, That is the Question”
Until the end of the last century there were no drugs approved for the treatment of juvenile idiopathic arthritis (JIA). This situation was revolutionized in the past 20 years thanks to 3 factors: the introduction in the USA and in Europe of paediatric legislations(1, 2), the availability of biologic disease-modifying anti-rheumatic drugs (b-DMARDs), and the existence of not-for-profit organizations with the mission to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres studies in children with paediatric rheumatic diseases.
Biological Products, Evidence-Based Medicine, Antirheumatic Agents, Humans, Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Evidence-Based Medicine; Humans; Randomized Controlled Trials as Topic, Arthritis, Juvenile, Randomized Controlled Trials as Topic
Biological Products, Evidence-Based Medicine, Antirheumatic Agents, Humans, Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Evidence-Based Medicine; Humans; Randomized Controlled Trials as Topic, Arthritis, Juvenile, Randomized Controlled Trials as Topic
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).3 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!